Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies
Cancer Chemotherapy and Pharmacology, 05/25/2012
Wang ZH et al. – Loss of expression of PTEN is a potential biomarker for resistance to anti–EGFR monoclonal therapy, particularly in metastatic colorectal cancer (mCRC) patients with KRAS wild type.



